Global TCR Engineered T-Cell Therapy 2018 Market Report; Launched via MarketResearchReports.com

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

T-Cell Receptors (TCR) and Chimeric Antigen Receptors (CAR) are the cutting edge of adoptive T-cell therapy. Both receptors deploy T-cells to target the tumor, but CAR T-cells (CAR-T) are limited to binding to cell surface antigens, while TCR T-cells (TCR-T) recognize peptides (derived from intracellular proteins) presented on the cell surface by the major histocompatibility complex (MHC) class I.

TCR-Ts have so far operated in the shadow of CAR-Ts, but may have the advantage in solid tumors. The first approved CD19-specific CAR-Ts are indicated for hematologic malignancies, but CAR-Ts were less successful against solid tumors.

This report „TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals“ published in May 2018 brings you up-to-date regarding key TCR-T players, key TCR-T technologies and product candidates, business models, deals and funding opportunities. The report analyzes the TCR-T pipelines and stakeholders in the field, especially focused and diversified TCR-T companies and their relationship with academia and major pharma/biotech. The report highlights the value of TCR-T assets in terms of partnering economic conditions, acquisition prices and financing rounds.

This report has been prepared by use of in-house databases and desktop search to identify and describe company, product, technology and business/financing profiles which then were evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities. Sources of information are provided by scientific and non-scientific references, e.g. press releases, stock exchange disclosures, presentations, annual reports, fact sheets and patent applications (with hyperlinks leading to the source of information).

Key questions answered:

• Which targets are chosen for developmen of TCR-Ts?
• How close are neoantigen-specific TCR-Ts to the clinic?
• Which technologies are used for generation of T-Cell Receptors?
• Has clinical proof-of-concept been shown for any TCR-T?
• How does the TCR-T pipeline look like?
• What manufacturing strategies and solutions have companies chosen?
• Are next generation TCR-Ts already in development?
• What are the key technologies for a successful TCR-T?
• Who are the key players in the TCR-T field?
• How tough is competition among TCR-T developers?
• Should companies be focused on TCR-Ts only or be diversified into various adoptive T-cell therapeutics?
• Which technologies and assets attract licensees?
• How is the financing situation for TCR-T?
• What are the key success factors for TCR-Ts?

Target audience:

• Leading Pharmaceutical companies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analyst
• CSO's
• CEO’s
• CIO’s
• COO’s
• Business development managers
• Investors
• Governments
• Agencies
• Industry organisations
• Banks

Spanning over 294 pages “TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals an industry analysis of technologies, stakeholders, deals & trends” report covers Executive Summary, Introduction, Overview & Background, Technologies, Pipeline, Manufacturing, Companies, Business Development & Financing, Outlook & Perspectives, References. This report Covered 33 Companies few are - Adaptimmune, Adicet Bio, Aeon Therapeutics Shanghai, AgenTus Therapeutics, Alpine Immune Science, Atreca, Bellicum Pharmaceuticals, BioNTech, Bluebird bio, Cell Medica, CRISPR Therapeutics.

Please visit this link for more details: http://mrr.cm/UD5

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Competitor Analysis: CDK9 and Mcl-1 Inhibitors - Visit at - http://mrr.cm/UDS

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins - Visit at - http://mrr.cm/UDT